EurekAlert!

C-Path’s TRxA announces $1 million award for drug development project in type 1 diabetes

TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
EurekAlert!

C-Path’s translational therapeutics accelerator announces new grant award for drug development project in type 1 diabetes

TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...
Chromatography Online

Pittcon Preview: Next-Generation Drug Development Enabled by Automation, Digitalization, and AI/ML

The session Next-Generation Drug Development Enabled by Automation, Digitalization, and AI/ML is scheduled to take place at Pittcon 2026 in San Antonio, TX, on Monday, March 9, from 8:30 am–10:40 am ...
BioWorld

Critical Path Institute funds development of QED-203 for advanced prostate cancer

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
Arizona Daily Star

C-Path brings drug-pipeline cooperation

The Tucson-based Critical Path Institute was founded in 2005 as a public-private partnership with the U.S. Food and Drug Administration. Its main goal is to improve the drug-development process so ...
KXAN

C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects

BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ -- The Innovative Health Initiative (IHI) and Critical Path Institute ® (C-Path) today announced the publication of a peer-reviewed paper in Nature ...